Bausch + Lomb reported strong Q3 2025 earnings and revenue surpassing expectations, leading to a revised full-year outlook. The company's stock has shown positive momentum, yet challenges remain, highlighting potential undervaluation with a Price-to-Sales ratio of 1.1x.